Clinical trials for autism drugs have been plagued with problems: bad design, the wrong measures, too broad a range of participants. All that is finally starting to change.
A new ‘knowledge engine’ collects reams of behavioral and sensory data to create highly sensitive outcome measures for autism drugs.
Our infographic displays efforts to develop treatments for fragile X syndrome. So far, none of them have passed muster in clinical trials.